Our research Organic Bioelectronic Neuropharmacology, electroceuticals for the nervous system - Our ambition is to supplement biochemical signaling with electronic functionalities using both galvanic (ion) and faradic (electron) processes. Traditional medicines are based on biochemical principles without regard to electrical properties. We focus on organic electronics that are self-assembled direc

https://www.multipark.lu.se/chemical-biology-therapeutics - 2025-07-27

Our research My group works with translational stem cell biology. The focus of my research is to understand cell fate specification in the developing brain and in human neural progenitor cells, using cell-based models of neuronal differentiation. Our current focus is to learn how to direct and efficiently drive controlled differentiation of human stem cells into subtype-specific neurons. We also d

https://www.multipark.lu.se/developmental-and-regenerative-neurobiology - 2025-07-27

Our research Neurovascular changes are now increasingly recognized as a common denominator of many neurodegenerative disorders. In my group, we examine how microvascular alterations at the blood-brain barrier contribute to the pathogenesis of neurodegeneration. Our special focus is on pericytes as key players in inflammation and neurodegeneration and potential target cells for brain repair. Using

https://www.multipark.lu.se/translational-neurology - 2025-07-27

Our research The Translational Neuroendocrine Research Unit (TNU) focuses on Huntington’s disease (HD). Furthermore, we study the spectrum of amyotrophic lateral sclerosis (ALS) and the behavioral variant of frontal temporal dementia (bvFTD). These are fatal neurodegenerative disorders without effective disease-modifying therapies. Although research has previously focused on the well-known disturb

https://www.multipark.lu.se/translational-neuroendocrinology - 2025-07-27

Our research Our group studies genetic causes of Parkinson’s disease (PD) and other neurological/neurodegenerative movement disorders. Emphasis presently lies on patients and families with inherited disease forms, where mutations in a single gene cause the disease. Such genetic disease forms offer the possibility to discover and study novel disease mechanisms. Genetic testing is increasingly used

https://www.multipark.lu.se/clinical-neurogenetics - 2025-07-27

Our research Research in the laboratory attempts to define pathogenic cellular and molecular mechanisms involved in synucleiopathies, in particular Parkinson's disease and multiple system atrophy, and Alzheimer's disease. Our work focuses on the interactions between glia and neurons. We are constantly developing new and robust human stem cell-based models which we utilize to understand cell autono

https://www.multipark.lu.se/stem-cell-laboratory-cns-disease-modeling - 2025-07-27

Our research Our research is focused on identifying cellular and molecular mechanisms contributing to circuit remodeling in the postischemic brain. In particular, we are interested in how the activation of dopamine signaling cascades modulates processes of adaptive neuronal plasticity. Identifying specific dopamine-driven targets may provide candidates for a recovery-enhancing adjuvant pharmacolog

https://www.multipark.lu.se/laboratory-experimental-brain-research - 2025-07-27

Our research We focus on finding protective factors for neurodegenerative disorders, with emphasis on Parkinson’s disease (PD). Our strategy is to identify risk factors in genes, lifestyle and environment, to learn about the underlying causes for disease, and how to interfere with these. In this quest, we combine molecular biology with in vitro and in vivo models and studies in clinical materials.

https://www.multipark.lu.se/translational-neurogenetics - 2025-07-27

Our research Our research centers on aging and neurodegenerative diseases. We aim to gain a better understanding of underlying disease mechanisms and aid in the development of better biomarkers for disease progression and clinical trials. We focus on characterizing the causes and effects of granular patterns of neurodegeneration, particularly in medial temporal lobe (MTL) subregions, which are sel

https://www.multipark.lu.se/medial-temporal-lab - 2025-07-27

Our research Our research uses reprogramming strategies to generate interneurons from novel cell sources with the aim to extensively define the subtype and function of these for therapeutic development, e.g. via interneuron cell replacement. For this, we are using reprogramming technology in animal models or human stem cell culture systems, together with electrophysiology, RNA sequencing, tracing

https://www.multipark.lu.se/regenerative-neurophysiology - 2025-07-27

Our research Alzheimer’s disease (AD)  is a multifaceted disease, among others characterized by Aβ plaques and tau neurofibrillary tangles. This highlights the need for a diversified drug portfolio. Tau pathology is a promising drug target due to its strong associations with synaptic density, atrophy, and cognition. We envision two treatment options to be potentially effective in halting or slowin

https://www.multipark.lu.se/tau-now - 2025-07-27

Our research We use Positron Emission Tomography (PET) to understand disease mechanisms and disease progression in neurodegenerative disorders. Our work focus on: 1) Parkinson’s disease (PD) and related “atypical” Parkinsonian Disorders. 2) tau PET imaging for diagnosis and tracking disease progression in Alzheimer’s Disease (AD) and other tauopathies such as Corticobasal Degeneration (CBD) and Pr

https://www.multipark.lu.se/neuropet-unit - 2025-07-27

Our research We study neurological diseases at the intersection between clinical research, biochemistry, and computer science. A key topic in our work is Alzheimer’s disease, where we study large patient cohorts using biochemistry, cell models, genetic analyses, advanced neuroimaging, and cognitive tests. To optimally use this multimodal data, we use state-of-the-art machine learning and artificia

https://www.multipark.lu.se/computational-neurology - 2025-07-27

Our research We study frontotemporal dementia, the second most common neurodegenerative dementing disorder. Our focus is twofold: improving the diagnostic process through the use of biomarkers (PET and fluid biomarkers), and increased understanding of the disease mechanisms, mainly using MRI. Also, we participate in the development of international guidelines for the diagnosis and management of th

https://www.multipark.lu.se/frontotemporal-dementia-research-unit - 2025-07-27

Our research My team focuses on developing accurate methods for early diagnosis of Alzheimer's and Parkinson's disease related disorders. We also aim to unravel the interplay between different pathologic events in humans with pre-symptomatic or prodromal disease, as well as to investigate different subtypes of the diseases.  Finally, we are focusing on improving clinical trials evaluating new dise

https://www.multipark.lu.se/clinical-memory-research-unit - 2025-07-27

Our research We are interested in how gene expression is regulated in the brain and how this process influences human brain evolution, neurodegenerative diseases, psychiatric disorders, and brain tumors. Our current focus is to study the role of epigenetic mechanisms and transposable elements. Our technical expertise includes CRISPR, reprogramming, bioinformatics, single-cell analysis, and human s

https://www.multipark.lu.se/laboratory-molecular-neurogenetics - 2025-07-27

High content screening (HCS) / Analysis (HCA). Cellomics, or HCS / HCA, enables automated acquisition, visualization and quantification of a large number of images:Automated fluorescence and brightfield microscopy Extraction of quantitative data from intensity and area measurementsHigh through-put formatExamples of dynamic processes that may be measured are: MigrationChanges in morphology, express

https://www.multipark.lu.se/infrastructures/cellomics-high-content-screeninganalysis - 2025-07-27

Our research Our main focus is understanding peripheral pathology in Huntington’s disease (HD) and to investigate its importance for disease pathogenesis and biomarkers. HD is the most common inherited neurodegenerative disorder and is often regarded as a model for both sporadic and inherited neurodegenerative diseases. Many clinical features of HD can be ascribed to the dysfunction and death of n

https://www.multipark.lu.se/brain-disease-biomarker-unit - 2025-07-27

Our researchOur research focuses on identifying new early mechanisms and biomarkers associated with Alzheimer's disease (AD) and thereby improve the development of new treatments and diagnostic tools. Our strategy is to investigate the effect of AD risk factors like stress, inflammation, metabolic changes, and amyloidogenesis, on different types of brain cells including pericytes, astrocytes, neur

https://www.multipark.lu.se/cognitive-disorder-research-unit - 2025-07-27

Our research Motor impairments are common among people with neurodegenerative diseases such as Parkinson’s disease (PD). In older people in general, some motor abilities seem to decline prior to the development of a major neurocognitive disorder, i.e. dementia. Our research primarily involves patients with PD and those at risk of developing dementia. We address health from a broad perspective, inc

https://www.multipark.lu.se/rehabmotor-aspects - 2025-07-27